LIALDA PACKAGE INSERT PDF

Check out Lialda for induction of remission in active mild to moderate UC and maintenance of UC remission. Read safety info including potential kidney. Shire US Manufacturing Inc.: LIALDA is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Lialda (mesalamine).

Author: Melmaran Zulkigore
Country: Pacific Islands
Language: English (Spanish)
Genre: Video
Published (Last): 22 April 2009
Pages: 160
PDF File Size: 15.50 Mb
ePub File Size: 8.33 Mb
ISBN: 332-8-72868-786-1
Downloads: 64587
Price: Free* [*Free Regsitration Required]
Uploader: Nele

E-mail this page or Web site to a friend or loved one by filling out the form below. Following Your Prescribed Treatment Plan. Tell your inert if you: Shire does not control the content of non-Shire Web sites, and this link does not constitute an endorsement by Shire of the site’s content.

Our privacy policy does not apply to this site. All other intellectual property rights are reserved.

E-mail to a Friend

You may need to adjust your Internet properties within your Web browser software, such as Microsoft Internet Explorer or Mozilla Firefox. Kidney problems have been reported with medications that contain mesalamine, such as Lialda.

All content on this Web site, including text, images, graphics, sound files, and their arrangement, belongs to Shire and is protected by international copyright laws. The information contained in this section of the site is intended for US health care professionals only. See Additional Important Safety Information. E-mail this page only.

  AMBURANA CEARENSIS PDF

inserh

Talk to your doctor about why Lialda may be right for you. Important Safety Information Do not take Lialda mesalamine if you are allergic to salicylates, such as aspirin, or medications that contain aspirin; aminosalicylates; mesalamine; or any other ingredients in Lialda.

All fields are required. Cookies are required to use some elements of this Web site.

Ulcerative Colitis (UC) Treatment | Lialda® (mesalamine)

Your e-mail address and that of the recipient will be used for transmission only and will not be used for any other purposes. E—mail this list of questions for the doctor — to yourself, a friend or a loved one — by filling out the form isnert. You must have JavaScript enabled on your computer to access this Web site feature. This link will take you to a Web site maintained by a third party, who is responsible for its content and privacy policy.

Please see Full Prescribing Information for Lialda mesalamine. This site is intended solely for US residents and is governed solely by US laws and government regulations. Click “Cancel” to return or “OK” to continue.

Please see our privacy policy for more information. Your doctor may check to see how your kidneys are working before starting Lialda and periodically while taking Lialda.

  IE3D TUTORIAL PDF

Lialda is a prescription medication approved for the induction of remission in patients with active, mild to moderate ulcerative colitis UC and for the maintenance of remission of UC. In clinical studies of Lialda, inflammation of the pancreas also occurred. If this happens to you, your doctor may tell you to stop taking Lialda. While Shire US Inc. For the induction of remission in patients with active, mild to moderate ulcerative colitis UC and for packagr maintenance of remission of UC.

The content may not be copied for commercial loalda or distribution, nor may these objects be downloaded, modified, or posted to other sites. Do not take Lialda mesalamine if you are allergic to salicylates, such as aspirin, or medications that contain aspirin; aminosalicylates; mesalamine; or any other ingredients in Lialda. Please review Shire’s Privacy Policy. We encourage you to read the privacy policy of every Web site you visit.

Click OK if you are a health care professional. You are encouraged to report negative packaage effects of prescription drugs to the FDA.